Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy

AIDS. 2020 Mar 1;34(3):483-486. doi: 10.1097/QAD.0000000000002431.

Abstract

: The pol gene from HIV-2-infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first-line regimen of zidovudine (AZT), lamivudine (3TC) and lopinavir/ritonavir (LPV/r). Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found in 58.8% (10/17) of the patients. Integrase inhibitors are warranted to treat these patients.

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Cabo Verde
  • Drug Resistance, Viral / genetics
  • HIV Infections* / drug therapy
  • HIV Protease Inhibitors* / therapeutic use
  • HIV-1* / genetics
  • HIV-2 / genetics
  • Humans
  • Lamivudine / therapeutic use
  • Lopinavir / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / therapeutic use
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • Lamivudine
  • Ritonavir